^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | zanidatamab (ZW25) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
Published date:
01/17/2023
Excerpt:
In 38 response-evaluable pts with HER2+ tumors, confirmed objective response rate (cORR) was 79% (95% CI: 63-90%) and disease control rate was 92% (95% CI: 79-98%); 3 pts achieved complete response….In pts with HER2+ mGEA, zani + chemo is a highly active treatment regimen with a manageable safety profile. This maturing data set demonstrates durable disease control with encouraging cORR, DOR, PFS and OS results.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.3_suppl.347
Trial ID:
Source:
Title:
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
Published date:
01/11/2021
Excerpt:
Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy)....GEA patients have been treated (zanidatamab Q2W + (paclitaxel [n = 11] or capecitabine [n = 6]); zanidatamab Q3W + capecitabine [n = 9])....patients with HER2-expressing GEA.
Secondary therapy:
capecitabine
Trial ID:
Source:
Title:
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
Published date:
01/11/2021
Excerpt:
Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy)....GEA patients have been treated (zanidatamab Q2W + (paclitaxel [n = 11] or capecitabine [n = 6]); zanidatamab Q3W + capecitabine [n = 9])....patients with HER2-expressing GEA.
Trial ID:
Source:
Title:
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
Published date:
01/11/2021
Excerpt:
Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy)....GEA patients have been treated (zanidatamab Q2W + (paclitaxel [n = 11] or capecitabine [n = 6]); zanidatamab Q3W + capecitabine [n = 9])....patients with HER2-expressing GEA.
Secondary therapy:
capecitabine; paclitaxel
Trial ID:
